Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy

Abstract Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leading to microangiopathic hemolytic anemia, platelet...

Full description

Bibliographic Details
Main Authors: Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain, Sean Rowell, Houry Leblebjian, Eileen Regan, Peter Czarnecki, Filippo Bagnoli, Niccolo’ Bolli, Paul Richardson, Helmut G. Rennke, Meletios A. Dimopoulos, Efstathios Kastritis, Giada Bianchi
Format: Article
Language:English
Published: Nature Publishing Group 2023-02-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00802-0

Internet

https://doi.org/10.1038/s41408-023-00802-0

Similar Items